China SXT Pharmaceuticals (SXTC) Equity Average (2019 - 2021)
Historic Equity Average for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q1 2021 value amounting to $17.2 million.
- China SXT Pharmaceuticals' Equity Average rose 6569.82% to $17.2 million in Q1 2021 from the same period last year, while for Mar 2021 it was $17.2 million, marking a year-over-year increase of 6569.82%. This contributed to the annual value of $14.7 million for FY2025, which is 261.5% up from last year.
- Per China SXT Pharmaceuticals' latest filing, its Equity Average stood at $17.2 million for Q1 2021, which was up 6569.82% from $14.0 million recorded in Q3 2020.
- In the past 5 years, China SXT Pharmaceuticals' Equity Average ranged from a high of $17.2 million in Q1 2021 and a low of $10.4 million during Q1 2020
- In the last 3 years, China SXT Pharmaceuticals' Equity Average had a median value of $12.6 million in 2019 and averaged $13.2 million.
- As far as peak fluctuations go, China SXT Pharmaceuticals' Equity Average surged by 2400.72% in 2020, and later skyrocketed by 6569.82% in 2021.
- China SXT Pharmaceuticals' Equity Average (Quarter) stood at $11.3 million in 2019, then rose by 24.01% to $14.0 million in 2020, then increased by 23.49% to $17.2 million in 2021.
- Its Equity Average was $17.2 million in Q1 2021, compared to $14.0 million in Q3 2020 and $10.4 million in Q1 2020.